Received Dec 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | N733B | — |
second dose was administered three weeks apart from the first dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 38-year-old male patient who received HBV (Engerix B) (batch number N733B, expiry date 27-AUG-2027) for prophylaxis. Concomitant products included Hepatitis b vaccine rHBsAg (yeast) (Engerix b). On 08-DEC-2025, the patient received the 2nd dose of Engerix B. On 08-DEC-2025, an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too short (Verbatim: second dose was administered three weeks apart from the first dose). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date:8-DEC-2025 The Vaccine Administration Facility was the same as primary reporter The reporter stated that, the second dose was administered three weeks apart from the first dose.